Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)

In early October 2026, Regeneron Pharmaceuticals reported new clinical data across oncology and obesity programs and expanded its long-running antibody alliance with Sanofi, which includes US$1.00 billion upfront and potential future milestone payments worth up to US$7.00 billion. These updates highlight Regeneron’s attempt to broaden its pipeline beyond current blockbusters, particularly through ubamatamab in low-grade serous ovarian cancer and next-generation long-acting immunology...